Charles Wu
Technik-/Wissenschafts-/F&E-Leiter bei Beijing Continent Pharmaceutical Co., Ltd.
Vermögen: - $ am 31.05.2024
Profil
Charles Wu is currently the Chief Technology Officer at Beijing Continent Pharmaceutical Co., Ltd.
He previously served as the Chief Executive Officer & Director at Gyre Therapeutics, Inc. from 2023 to 2024.
Dr. Wu holds an MBA from Tulane University, a doctorate from the University of Maryland, and an undergraduate degree from the University of Science & Technology of China.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
-.--% | 19.03.2024 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Charles Wu
| Unternehmen | Position | Beginn |
|---|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2020 |
Ehemalige bekannte Positionen von Charles Wu
| Unternehmen | Position | Ende |
|---|
Ausbildung von Charles Wu
| University of Science & Technology of China | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
| Tulane University (Louisiana) | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
